deaths (OS)progression or deaths (PFS)RFS/DFS

metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)

versus pegylated liposomal doxorubicin
avelumab alone vs. pegylated liposomal doxorubicin 1 1.0better0.35.084 %1.0better0.35.0100 %-
avelumab plus pegylated liposomal doxorubicin vs. pegylated liposomal doxorubicin 1 1.0better0.35.081 %1.0better0.35.091 %-